Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
CompanyDeals

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Innovent Biologics' Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
Company

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Santen's Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China's NMPA for Myopia Progression
CompanyDrug

Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression

CompanyDeals

Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD‑1005, Novel Tumor Microenvironment‑Activated CD47 Antibody

CompanyMedical Device

Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System

CompanyDrug

TenNor Therapeutics Reports Positive Phase IIa Top‑Line Results for TNP‑2092 in Prosthetic Joint Infection; First‑in‑Class Triple‑Target Candidate Advances to Phase IIb

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
CompanyDrug

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

CompanyDrug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

CompanyDeals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

CompanyDrug

Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC

CompanyDrug

Yipinhong’s AR882 Meets Primary Endpoint in Phase 3 Gout Trial, Outperforming Febuxostat on Uric Acid Reduction